About Gland Pharma Ltd
Data last updated: 05 January 2026
Gland Pharma Ltd is a public limited company based in Medchal Malkajgiri District Hyderabad, Telangana, India, a subsidiary of Fosun Pharma Industrial Pte Ltd. It specialises in medical and laboratory equipment, a part of the broader healthcare sector. Incorporated on 20 March 1978, the company has been in operation for over 48 years.
Registered with ROC Hyderabad under CIN U24239AP1978PLC002276. Listed on BSE: 543245 and NSE: GLAND.
Capital: an authorised share capital of ₹56.3 Cr and a paid-up capital of ₹16.48 Cr. Formerly known as Gland Pharma Pvt Ltd. It is led by directors including Essaji Goolam Vahanvati and Udo Jahannes Vetter.
Last AGM: 28 August 2025. Financial statements filed for year ended 31 March 2025. Office: Medchal Malkajgiri District Hyderabad, Telangana.
As per the financials filed for FY 2025, the company reported a revenue of ₹5,830.11 Cr, a growth of 0% compared to the previous year.
The company has a workforce of approximately 4,769 employees as per the latest available data. It operates as a subsidiary of Fosun Pharma Industrial Pte Ltd.
The company is associated with 1 brand - Gland Pharma. As per MCA filings, the company has satisfied charges of ₹566.83 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glandpharma.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered AddressSy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, Amma(M), Medchal Malkajgiri District Hyderabad, Telangana, India – 500043
-
IndustryHealthcare, Medical & Laboratory Equipment
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Gland Pharma Ltd
Gland Pharma Ltd has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1978PLC002276, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239TG1978PLC002276 | Current |
| U24239AP1978PLC002276 | Previous |
| U24239TG1978PLC002276 | Previous |
Associated Brands with Gland Pharma Ltd
Gland Pharma Ltd operates one associated brand: Gland Pharma. These brands represent Gland Pharma Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Generic injectable drugs are manufactured across therapeutic segments. | glandpharma.com |
Competitors & Alternatives of Gland Pharma Ltd
Brands and companies operating in the same space as Gland Pharma Ltd include Exela Pharma, Luoxin Pharmaceutical Group, Summit Biosciences and 5 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Exela Pharma
|
Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | Lenoir, United States, United States | 2005 |
Luoxin Pharmaceutical Group
|
Developer and manufacturer of pharmaceutical products | Linyi, China, China | 2006 |
Summit Biosciences
|
Nasal spray drug products are developed, manufactured, and commercialized. | Lexington, United States, United States | 2008 |
August Bioservices
|
Diversified research services for clinical solutions are offered. | Nashville, United States, United States | 2017 |
ApiJect
|
Medicine injectors are manufactured by ApiJect for medical applications. | Stamford, United States, United States | 2015 |
Vetter Pharma
|
CDMO specializing in aseptically prefilled syringe systems, cartridges and vials. | Ravensburg, Germany, Germany | 1950 |
INCOG BioPharma Services
|
Injectable drug products are manufactured by this biopharma CDMO. | United States | 2020 |
Nitin Lifesciences
|
CMO of small volume parenteral injectables | Karnal, India, India | 1994 |
Business Activity of Gland Pharma Ltd
Gland Pharma Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Gland Pharma Ltd
Gland Pharma Ltd is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Gland Pharma Ltd
Gland Pharma Ltd is currently managed by 12 directors, with 32 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Essaji Goolam Vahanvati | Director | 30 Sep 2020 | 5 Years 9 Months | Current |
|
Udo Jahannes Vetter
Also directs:
Paschal Form Work (India) Private Limited
|
Director | 07 Feb 2018 | 8 Years 5 Months | Current |
| Jia Ai Zhang | Director | 17 May 2021 | 5 Years 1 Months | Current |
| Naina Lal Kidwai | Director | 17 May 2021 | 5 Years 1 Months | Current |
| Shyamakant Binda Giri | Ceo | 16 Jan 2025 | 1 Years 5 Months | Current |
| Satyanarayana Murthy Chavali | Director | 20 Nov 2018 | 7 Years 7 Months | Current |
Financials of Gland Pharma Ltd FY 2026 filings available
Gland Pharma Ltd reported revenue of ₹6,430.65 Cr (up 14.5% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹6,430.65 Cr | ₹5,616.5 Cr | ₹5,664.72 Cr | ₹3,624.6 Cr | ₹4,400.71 Cr | ₹3,462.88 Cr |
| Other Income | ₹316.33 Cr | ₹213.61 Cr | ₹170.24 Cr | ₹240.46 Cr | ₹223.94 Cr | ₹134.78 Cr |
| Total Income | ₹6,746.98 Cr | ₹5,830.11 Cr | ₹5,834.96 Cr | ₹3,865.06 Cr | ₹4,624.65 Cr | ₹3,597.65 Cr |
| Cost of Materials Consumed | ₹2,239.75 Cr | ₹1,972.48 Cr | ₹2,022.14 Cr | ₹1,716.75 Cr | ₹2,046.86 Cr | ₹1,749.16 Cr |
| Purchases of Stock-in-Trade | ₹6.6 Cr | ₹14.49 Cr | ₹23.07 Cr | ₹15.59 Cr | ₹25.67 Cr | ₹16.2 Cr |
| Changes in Inventories | -₹3.42 Cr | ₹103.41 Cr | ₹127.89 Cr | -₹46.92 Cr | ₹36.69 Cr | -₹273.49 Cr |
| Employee Benefit Expense | ₹1,628.84 Cr | ₹1,401.56 Cr | ₹1,256.89 Cr | ₹403.26 Cr | ₹338.57 Cr | ₹311.36 Cr |
| Finance Costs | ₹33.28 Cr | ₹42 Cr | ₹26.2 Cr | ₹7.45 Cr | ₹5.24 Cr | ₹3.41 Cr |
| Depreciation & Amortisation | ₹423.67 Cr | ₹377.87 Cr | ₹344.57 Cr | ₹146.74 Cr | ₹110.3 Cr | ₹98.78 Cr |
| Other Expenses | ₹929.34 Cr | ₹855.64 Cr | ₹901.67 Cr | ₹511.15 Cr | ₹442.77 Cr | ₹357.42 Cr |
| Total Expenses | ₹5,258.05 Cr | ₹4,767.45 Cr | ₹4,702.42 Cr | ₹2,754.02 Cr | ₹3,006.09 Cr | ₹2,262.84 Cr |
| Profit Before Exceptional Items & Tax | ₹1,488.93 Cr | ₹1,062.66 Cr | ₹1,132.54 Cr | ₹1,111.04 Cr | ₹1,618.55 Cr | ₹1,334.81 Cr |
| Exceptional Items | -₹24.35 Cr | ₹0 | ₹0 | -₹56.46 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹1,464.58 Cr | ₹1,062.66 Cr | ₹1,132.54 Cr | ₹1,054.58 Cr | ₹1,618.55 Cr | ₹1,334.81 Cr |
| Total Tax Expense | ₹437.26 Cr | ₹364.13 Cr | ₹360.08 Cr | ₹273.54 Cr | ₹406.89 Cr | ₹337.85 Cr |
| Net Profit | ₹1,027.32 Cr | ₹698.53 Cr | ₹772.46 Cr | ₹781.04 Cr | ₹1,211.66 Cr | ₹996.96 Cr |
| attributable to Owners | ₹1,027.32 Cr | ₹698.53 Cr | ₹772.46 Cr | ₹781.04 Cr | ₹1,211.66 Cr | ₹996.96 Cr |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹430.99 Cr | ₹55.39 Cr | -₹7.87 Cr | -₹1.44 Cr | -₹45.8 Lakh | -₹87.2 Lakh |
| Total Comprehensive Income | ₹1,458.3 Cr | ₹753.91 Cr | ₹764.6 Cr | ₹779.61 Cr | ₹1,211.21 Cr | ₹996.09 Cr |
| EBITDA (computed) | ₹1,945.87 Cr | ₹1,482.53 Cr | ₹1,503.31 Cr | ₹1,265.23 Cr | ₹1,734.09 Cr | ₹1,437 Cr |
| Basic EPS | ₹62.35 | ₹42.40 | ₹46.90 | ₹47.44 | ₹73.81 | ₹63.07 |
| Diluted EPS | ₹62.28 | ₹42.40 | ₹46.89 | ₹47.43 | ₹73.64 | ₹62.99 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹12,511 Cr | ₹11,225 Cr | ₹10,661 Cr | ₹8,777.54 Cr |
| Non-current Assets | ₹4,984.06 Cr | ₹4,441.98 Cr | ₹5,016.09 Cr | ₹1,876.73 Cr |
| Current Assets | ₹7,526.79 Cr | ₹6,782.94 Cr | ₹5,645.15 Cr | ₹6,900.81 Cr |
| Property, Plant & Equipment | ₹4,051.97 Cr | ₹3,750.54 Cr | ₹3,541.31 Cr | ₹1,558.5 Cr |
| Inventories | ₹1,743.89 Cr | ₹1,685.22 Cr | ₹1,655.24 Cr | ₹1,945.3 Cr |
| Trade Receivables | ₹1,891.38 Cr | ₹1,516.53 Cr | ₹1,558.69 Cr | ₹871.39 Cr |
| Cash & Equivalents | ₹3,359.11 Cr | ₹2,556.21 Cr | ₹357.09 Cr | ₹1,908.9 Cr |
| Equity (Net Worth) | ₹10,358 Cr | ₹9,150.74 Cr | ₹8,723.84 Cr | ₹7,958.72 Cr |
| Equity Share Capital | ₹16.48 Cr | ₹16.48 Cr | ₹16.47 Cr | ₹16.47 Cr |
| Borrowings (Non-current) | ₹69.93 Cr | ₹77.66 Cr | ₹106.54 Cr | ₹3.26 Cr |
| Borrowings (Current) | ₹173.44 Cr | ₹191.55 Cr | ₹213.24 Cr | ₹56 Lakh |
| Total Debt (computed) | ₹243.36 Cr | ₹269.21 Cr | ₹319.78 Cr | ₹3.82 Cr |
| Current Liabilities | ₹1,608.4 Cr | ₹1,564.85 Cr | ₹1,398.36 Cr | ₹729.13 Cr |
| Total Liabilities | ₹2,152.9 Cr | ₹2,074.18 Cr | ₹1,937.4 Cr | ₹818.81 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,031.39 Cr | ₹914.73 Cr | ₹996.8 Cr | ₹363.97 Cr | ₹790.77 Cr |
| Investing Cash Flow | ₹137.73 Cr | ₹1,704.74 Cr | -₹1,756.91 Cr | ₹1,208.19 Cr | -₹1,002.62 Cr |
| Financing Cash Flow | -₹416.97 Cr | -₹433.48 Cr | -₹799.42 Cr | ₹14.92 Cr | ₹34.9 Cr |
| Capital Expenditure | ₹490.76 Cr | ₹384.54 Cr | ₹389.93 Cr | ₹220.93 Cr | ₹511.33 Cr |
| Free Cash Flow (computed) | ₹540.62 Cr | ₹530.19 Cr | ₹606.87 Cr | ₹143.04 Cr | ₹279.44 Cr |
| Dividends Paid | ₹296.55 Cr | ₹329.49 Cr | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹802.9 Cr | ₹2,199.12 Cr | -₹1,551.81 Cr | ₹1,590.08 Cr | -₹173.64 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,742.79 Cr | ₹1,695.36 Cr | ₹1,486.88 Cr | ₹1,505.62 Cr | ₹1,424.91 Cr | ₹1,384.05 Cr | ₹1,405.83 Cr | ₹1,401.71 Cr | ₹1,537.45 Cr | ₹1,545.16 Cr | ₹1,373.42 Cr | ₹1,208.69 Cr |
| Other Income | ₹111.47 Cr | ₹63.17 Cr | ₹84.16 Cr | ₹57.53 Cr | ₹44.03 Cr | ₹58.49 Cr | ₹59.66 Cr | ₹51.43 Cr | ₹42.15 Cr | ₹37.39 Cr | ₹53.16 Cr | ₹37.54 Cr |
| Total Income | ₹1,854.26 Cr | ₹1,758.54 Cr | ₹1,571.04 Cr | ₹1,563.15 Cr | ₹1,468.94 Cr | ₹1,442.55 Cr | ₹1,465.49 Cr | ₹1,453.14 Cr | ₹1,579.6 Cr | ₹1,582.55 Cr | ₹1,426.58 Cr | ₹1,246.24 Cr |
| Cost of Materials Consumed | ₹594.07 Cr | ₹529.89 Cr | ₹558.43 Cr | ₹557.36 Cr | ₹587.57 Cr | ₹437.38 Cr | ₹485.88 Cr | ₹461.65 Cr | ₹574.69 Cr | ₹464 Cr | ₹517.92 Cr | ₹465.53 Cr |
| Purchases of Stock-in-Trade | ₹2.28 Cr | ₹1.5 Cr | ₹1.94 Cr | ₹88.1 Lakh | ₹3.1 Cr | ₹2.15 Cr | ₹2.66 Cr | ₹6.58 Cr | ₹6.76 Cr | ₹6.38 Cr | ₹6.13 Cr | ₹3.79 Cr |
| Changes in Inventories | -₹5.02 Cr | ₹45.26 Cr | -₹6.56 Cr | -₹37.11 Cr | -₹102.71 Cr | ₹23.18 Cr | ₹86.93 Cr | ₹96.02 Cr | ₹17.94 Cr | ₹128.86 Cr | -₹2.49 Cr | -₹16.42 Cr |
| Employee Benefit Expense | ₹411.57 Cr | ₹424.2 Cr | ₹385.03 Cr | ₹408.04 Cr | ₹373.37 Cr | ₹342.86 Cr | ₹329.81 Cr | ₹355.53 Cr | ₹351.61 Cr | ₹345.33 Cr | ₹304.95 Cr | ₹255 Cr |
| Finance Costs | ₹10.03 Cr | ₹3.93 Cr | ₹7.82 Cr | ₹11.5 Cr | ₹7.45 Cr | ₹22.82 Cr | ₹6.11 Cr | ₹5.62 Cr | ₹9.96 Cr | ₹5.28 Cr | ₹6.05 Cr | ₹4.92 Cr |
| Depreciation & Amortisation | ₹108.66 Cr | ₹107.65 Cr | ₹106.31 Cr | ₹101.05 Cr | ₹95.76 Cr | ₹96.33 Cr | ₹93.83 Cr | ₹91.96 Cr | ₹92.61 Cr | ₹105.34 Cr | ₹81.3 Cr | ₹65.32 Cr |
| Other Expenses | ₹226.87 Cr | ₹259.64 Cr | ₹234.15 Cr | ₹208.69 Cr | ₹216.08 Cr | ₹218.53 Cr | ₹203.5 Cr | ₹217.53 Cr | ₹227.81 Cr | ₹244.2 Cr | ₹222.83 Cr | ₹206.83 Cr |
| Total Expenses | ₹1,348.46 Cr | ₹1,372.06 Cr | ₹1,287.12 Cr | ₹1,250.41 Cr | ₹1,180.61 Cr | ₹1,143.24 Cr | ₹1,208.71 Cr | ₹1,234.89 Cr | ₹1,281.37 Cr | ₹1,299.39 Cr | ₹1,136.69 Cr | ₹984.97 Cr |
| Profit Before Exceptional Items & Tax | ₹505.8 Cr | ₹386.47 Cr | ₹283.92 Cr | ₹312.74 Cr | ₹288.33 Cr | ₹299.3 Cr | ₹256.78 Cr | ₹218.25 Cr | ₹298.23 Cr | ₹283.16 Cr | ₹289.89 Cr | ₹261.27 Cr |
| Exceptional Items | ₹0 | -₹24.35 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹505.8 Cr | ₹362.13 Cr | ₹283.92 Cr | ₹312.74 Cr | ₹288.33 Cr | ₹299.3 Cr | ₹256.78 Cr | ₹218.25 Cr | ₹298.23 Cr | ₹283.16 Cr | ₹289.89 Cr | ₹261.27 Cr |
| Total Tax Expense | ₹139.12 Cr | ₹100.65 Cr | ₹100.23 Cr | ₹97.26 Cr | ₹101.79 Cr | ₹94.61 Cr | ₹93.25 Cr | ₹74.48 Cr | ₹105.81 Cr | ₹91.3 Cr | ₹95.81 Cr | ₹67.16 Cr |
| Net Profit | ₹366.68 Cr | ₹261.48 Cr | ₹183.68 Cr | ₹215.48 Cr | ₹186.54 Cr | ₹204.69 Cr | ₹163.53 Cr | ₹143.76 Cr | ₹192.42 Cr | ₹191.86 Cr | ₹194.08 Cr | ₹194.1 Cr |
| attributable to Owners | ₹366.68 Cr | ₹261.48 Cr | ₹183.68 Cr | ₹215.48 Cr | ₹186.54 Cr | ₹204.69 Cr | ₹163.53 Cr | ₹143.76 Cr | ₹192.42 Cr | ₹191.86 Cr | ₹194.08 Cr | ₹194.1 Cr |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹100.91 Cr | ₹40.76 Cr | ₹102.83 Cr | ₹186.49 Cr | ₹64.53 Cr | -₹93.27 Cr | ₹96.33 Cr | -₹12.2 Cr | -₹42.59 Cr | ₹74.99 Cr | -₹15.61 Cr | -₹24.65 Cr |
| Total Comprehensive Income | ₹467.59 Cr | ₹302.23 Cr | ₹286.51 Cr | ₹401.97 Cr | ₹251.07 Cr | ₹111.42 Cr | ₹259.86 Cr | ₹131.57 Cr | ₹149.83 Cr | ₹266.84 Cr | ₹178.47 Cr | ₹169.46 Cr |
| EBITDA (computed) | ₹624.49 Cr | ₹498.05 Cr | ₹398.05 Cr | ₹425.29 Cr | ₹391.54 Cr | ₹418.45 Cr | ₹356.72 Cr | ₹315.82 Cr | ₹400.8 Cr | ₹393.78 Cr | ₹377.23 Cr | ₹331.5 Cr |
| Basic EPS | ₹22.26 | ₹15.87 | ₹11.15 | ₹13.08 | ₹11.32 | ₹12.42 | ₹9.93 | ₹8.73 | ₹11.68 | ₹11.65 | ₹11.78 | ₹11.79 |
| Diluted EPS | ₹22.23 | ₹15.87 | ₹11.15 | ₹13.08 | ₹11.32 | ₹12.42 | ₹9.93 | ₹8.73 | ₹11.68 | ₹11.65 | ₹11.78 | ₹11.78 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹4,552.09 Cr | ₹4,116.15 Cr | ₹4,167.43 Cr | ₹3,616.53 Cr | ₹4,400.71 Cr | ₹3,462.88 Cr |
| Other Income | ₹303.9 Cr | ₹215.08 Cr | ₹166.67 Cr | ₹240.46 Cr | ₹223.94 Cr | ₹134.78 Cr |
| Total Income | ₹4,855.99 Cr | ₹4,331.22 Cr | ₹4,334.09 Cr | ₹3,856.99 Cr | ₹4,624.65 Cr | ₹3,597.65 Cr |
| Cost of Materials Consumed | ₹1,795.22 Cr | ₹1,585.86 Cr | ₹1,709.74 Cr | ₹1,716.75 Cr | ₹2,046.86 Cr | ₹1,749.16 Cr |
| Purchases of Stock-in-Trade | ₹6.6 Cr | ₹14.49 Cr | ₹23.14 Cr | ₹15.59 Cr | ₹25.67 Cr | ₹16.2 Cr |
| Changes in Inventories | -₹6.67 Cr | ₹130.25 Cr | ₹87.43 Cr | -₹46.92 Cr | ₹36.69 Cr | -₹273.49 Cr |
| Employee Benefit Expense | ₹528.82 Cr | ₹439.02 Cr | ₹409.95 Cr | ₹399.7 Cr | ₹338.57 Cr | ₹311.36 Cr |
| Finance Costs | ₹18.07 Cr | ₹22.84 Cr | ₹7.84 Cr | ₹7.41 Cr | ₹5.24 Cr | ₹3.41 Cr |
| Depreciation & Amortisation | ₹176.24 Cr | ₹169.27 Cr | ₹162.11 Cr | ₹146.74 Cr | ₹110.3 Cr | ₹98.78 Cr |
| Other Expenses | ₹565.04 Cr | ₹503.91 Cr | ₹528.39 Cr | ₹512.85 Cr | ₹442.29 Cr | ₹357.38 Cr |
| Total Expenses | ₹3,083.33 Cr | ₹2,865.64 Cr | ₹2,928.6 Cr | ₹2,752.13 Cr | ₹3,005.61 Cr | ₹2,262.8 Cr |
| Profit Before Exceptional Items & Tax | ₹1,772.66 Cr | ₹1,465.59 Cr | ₹1,405.5 Cr | ₹1,104.86 Cr | ₹1,619.04 Cr | ₹1,334.85 Cr |
| Exceptional Items | -₹24.35 Cr | ₹0 | ₹0 | -₹56.46 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹1,748.31 Cr | ₹1,465.59 Cr | ₹1,405.5 Cr | ₹1,048.4 Cr | ₹1,619.04 Cr | ₹1,334.85 Cr |
| Total Tax Expense | ₹448.76 Cr | ₹375.83 Cr | ₹362.17 Cr | ₹272.58 Cr | ₹406.89 Cr | ₹337.85 Cr |
| Net Profit | ₹1,299.55 Cr | ₹1,089.75 Cr | ₹1,043.33 Cr | ₹775.83 Cr | ₹1,212.16 Cr | ₹997.01 Cr |
| attributable to Owners | - | - | - | - | - | ₹997.01 Cr |
| attributable to NCI | - | - | - | - | - | ₹0 |
| Other Comprehensive Income | ₹6.47 Cr | -₹2.93 Cr | -₹1.86 Cr | -₹2.25 Cr | -₹38.5 Lakh | -₹87.1 Lakh |
| Total Comprehensive Income | ₹1,306.03 Cr | ₹1,086.83 Cr | ₹1,041.47 Cr | ₹773.57 Cr | ₹1,211.77 Cr | ₹996.13 Cr |
| EBITDA (computed) | ₹1,966.97 Cr | ₹1,657.69 Cr | ₹1,575.45 Cr | ₹1,259.01 Cr | ₹1,734.58 Cr | ₹1,437.04 Cr |
| Basic EPS | ₹78.88 | ₹66.15 | ₹63.35 | ₹47.12 | ₹73.84 | ₹63.07 |
| Diluted EPS | ₹78.78 | ₹66.15 | ₹63.33 | ₹47.11 | ₹73.67 | ₹62.99 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹11,607 Cr | ₹10,422 Cr | ₹9,541.09 Cr | ₹8,773.18 Cr |
| Non-current Assets | ₹5,185 Cr | ₹4,654.66 Cr | ₹4,969.76 Cr | ₹1,884.84 Cr |
| Current Assets | ₹6,422.22 Cr | ₹5,766.96 Cr | ₹4,571.33 Cr | ₹6,888.34 Cr |
| Property, Plant & Equipment | ₹1,683.94 Cr | ₹1,735.86 Cr | ₹1,682.47 Cr | ₹1,558.5 Cr |
| Inventories | ₹1,265.2 Cr | ₹1,254.23 Cr | ₹1,260.21 Cr | ₹1,945.3 Cr |
| Trade Receivables | ₹1,520.69 Cr | ₹1,142.9 Cr | ₹1,171.4 Cr | ₹862.84 Cr |
| Cash & Equivalents | ₹3,177.64 Cr | ₹2,432.62 Cr | ₹116.21 Cr | ₹1,905.22 Cr |
| Equity (Net Worth) | ₹10,810 Cr | ₹9,755.1 Cr | ₹8,995.29 Cr | ₹7,953.3 Cr |
| Equity Share Capital | ₹16.48 Cr | ₹16.48 Cr | ₹16.47 Cr | ₹16.47 Cr |
| Borrowings (Non-current) | ₹0 | ₹1.11 Cr | ₹2.55 Cr | ₹3.26 Cr |
| Borrowings (Current) | ₹0 | ₹1.44 Cr | ₹71 Lakh | ₹56 Lakh |
| Total Debt (computed) | ₹0 | ₹2.55 Cr | ₹3.26 Cr | ₹3.82 Cr |
| Current Liabilities | ₹633.03 Cr | ₹523.77 Cr | ₹414.2 Cr | ₹730.2 Cr |
| Total Liabilities | ₹797.18 Cr | ₹666.52 Cr | ₹545.8 Cr | ₹819.88 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹1,135.23 Cr | ₹1,073.67 Cr | ₹1,135.97 Cr | ₹367.89 Cr | ₹791.29 Cr |
| Investing Cash Flow | -₹95.56 Cr | ₹1,578.2 Cr | -₹2,923.92 Cr | ₹1,208.22 Cr | -₹1,010.23 Cr |
| Financing Cash Flow | -₹316.18 Cr | -₹339.54 Cr | -₹7.4 Cr | ₹14.92 Cr | ₹34.9 Cr |
| Capital Expenditure | ₹217.93 Cr | ₹135.11 Cr | ₹233.59 Cr | ₹220.93 Cr | ₹511.33 Cr |
| Free Cash Flow (computed) | ₹917.3 Cr | ₹938.56 Cr | ₹902.38 Cr | ₹146.96 Cr | ₹279.96 Cr |
| Dividends Paid | ₹296.55 Cr | ₹329.49 Cr | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹745.02 Cr | ₹2,316.42 Cr | -₹1,789.01 Cr | ₹1,594.04 Cr | -₹180.73 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,261.59 Cr | ₹1,177.51 Cr | ₹1,074.15 Cr | ₹1,038.84 Cr | ₹1,030.35 Cr | ₹1,010.78 Cr | ₹1,062.99 Cr | ₹1,012.02 Cr | ₹1,174.83 Cr | ₹1,097.86 Cr | ₹1,010.67 Cr | ₹884.07 Cr |
| Other Income | ₹106.36 Cr | ₹60.21 Cr | ₹82.59 Cr | ₹54.74 Cr | ₹43.72 Cr | ₹65.06 Cr | ₹57.8 Cr | ₹48.49 Cr | ₹46.96 Cr | ₹43.39 Cr | ₹41.11 Cr | ₹35.21 Cr |
| Total Income | ₹1,367.95 Cr | ₹1,237.72 Cr | ₹1,156.74 Cr | ₹1,093.58 Cr | ₹1,074.07 Cr | ₹1,075.85 Cr | ₹1,120.79 Cr | ₹1,060.51 Cr | ₹1,221.79 Cr | ₹1,141.25 Cr | ₹1,051.78 Cr | ₹919.28 Cr |
| Cost of Materials Consumed | ₹460.96 Cr | ₹434.85 Cr | ₹459.59 Cr | ₹439.82 Cr | ₹469.39 Cr | ₹348.91 Cr | ₹399.87 Cr | ₹367.69 Cr | ₹482.88 Cr | ₹378.43 Cr | ₹456.63 Cr | ₹391.8 Cr |
| Purchases of Stock-in-Trade | ₹2.28 Cr | ₹1.5 Cr | ₹1.94 Cr | ₹88.1 Lakh | ₹3.1 Cr | ₹2.15 Cr | ₹2.67 Cr | ₹6.58 Cr | ₹6.83 Cr | ₹6.38 Cr | ₹6.13 Cr | ₹3.79 Cr |
| Changes in Inventories | ₹21.55 Cr | ₹27.93 Cr | -₹41.93 Cr | -₹14.22 Cr | -₹67.28 Cr | ₹25.53 Cr | ₹67.74 Cr | ₹104.26 Cr | ₹26.97 Cr | ₹103.7 Cr | -₹22.74 Cr | -₹20.49 Cr |
| Employee Benefit Expense | ₹133.96 Cr | ₹134.14 Cr | ₹132.28 Cr | ₹128.44 Cr | ₹119.7 Cr | ₹105.36 Cr | ₹106.29 Cr | ₹107.68 Cr | ₹107.87 Cr | ₹99.29 Cr | ₹99.88 Cr | ₹102.91 Cr |
| Finance Costs | ₹6.17 Cr | ₹50.2 Lakh | ₹3.97 Cr | ₹7.44 Cr | ₹3.45 Cr | ₹18.31 Cr | ₹17.2 Lakh | ₹91.1 Lakh | ₹4.53 Cr | ₹79.9 Lakh | ₹91.4 Lakh | ₹1.6 Cr |
| Depreciation & Amortisation | ₹43.11 Cr | ₹44.53 Cr | ₹44.84 Cr | ₹43.77 Cr | ₹43.07 Cr | ₹43.77 Cr | ₹41.62 Cr | ₹40.82 Cr | ₹42.56 Cr | ₹40.33 Cr | ₹40.24 Cr | ₹38.98 Cr |
| Other Expenses | ₹135.13 Cr | ₹157.46 Cr | ₹147.38 Cr | ₹125.07 Cr | ₹111.32 Cr | ₹137.69 Cr | ₹122.63 Cr | ₹132.27 Cr | ₹117.46 Cr | ₹140.57 Cr | ₹123.67 Cr | ₹146.7 Cr |
| Total Expenses | ₹803.15 Cr | ₹800.92 Cr | ₹748.07 Cr | ₹731.19 Cr | ₹682.75 Cr | ₹681.72 Cr | ₹740.98 Cr | ₹760.2 Cr | ₹789.1 Cr | ₹769.5 Cr | ₹704.72 Cr | ₹665.29 Cr |
| Profit Before Exceptional Items & Tax | ₹564.8 Cr | ₹436.8 Cr | ₹408.67 Cr | ₹362.38 Cr | ₹391.32 Cr | ₹394.13 Cr | ₹379.82 Cr | ₹300.32 Cr | ₹432.69 Cr | ₹371.76 Cr | ₹347.06 Cr | ₹253.99 Cr |
| Exceptional Items | ₹0 | -₹24.35 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹564.8 Cr | ₹412.46 Cr | ₹408.67 Cr | ₹362.38 Cr | ₹391.32 Cr | ₹394.13 Cr | ₹379.82 Cr | ₹300.32 Cr | ₹432.69 Cr | ₹371.76 Cr | ₹347.06 Cr | ₹253.99 Cr |
| Total Tax Expense | ₹144.35 Cr | ₹104.61 Cr | ₹106.68 Cr | ₹93.13 Cr | ₹101.32 Cr | ₹99.01 Cr | ₹98.11 Cr | ₹77.39 Cr | ₹111.28 Cr | ₹94.95 Cr | ₹89.54 Cr | ₹66.41 Cr |
| Net Profit | ₹420.45 Cr | ₹307.85 Cr | ₹302 Cr | ₹269.26 Cr | ₹290 Cr | ₹295.12 Cr | ₹281.71 Cr | ₹222.92 Cr | ₹321.41 Cr | ₹276.81 Cr | ₹257.53 Cr | ₹187.58 Cr |
| Other Comprehensive Income | ₹5.59 Cr | ₹20.2 Lakh | ₹1.41 Cr | -₹73.1 Lakh | -₹4.59 Cr | ₹55.5 Lakh | ₹1.58 Cr | -₹46.5 Lakh | -₹1.95 Cr | ₹2.9 Lakh | ₹62.1 Lakh | -₹56.3 Lakh |
| Total Comprehensive Income | ₹426.04 Cr | ₹308.05 Cr | ₹303.41 Cr | ₹268.53 Cr | ₹285.41 Cr | ₹295.68 Cr | ₹283.29 Cr | ₹222.46 Cr | ₹319.46 Cr | ₹276.83 Cr | ₹258.15 Cr | ₹187.02 Cr |
| EBITDA (computed) | ₹614.07 Cr | ₹481.83 Cr | ₹457.48 Cr | ₹413.59 Cr | ₹437.84 Cr | ₹456.21 Cr | ₹421.6 Cr | ₹342.04 Cr | ₹479.79 Cr | ₹412.88 Cr | ₹388.21 Cr | ₹294.57 Cr |
| Basic EPS | ₹25.52 | ₹18.68 | ₹18.33 | ₹16.34 | ₹17.60 | ₹17.91 | ₹17.10 | ₹13.53 | ₹19.51 | ₹16.81 | ₹15.64 | ₹11.39 |
| Diluted EPS | ₹25.49 | ₹18.68 | ₹18.33 | ₹16.34 | ₹17.60 | ₹17.91 | ₹17.10 | ₹13.53 | ₹19.51 | ₹16.80 | ₹15.63 | ₹11.39 |
Board & Governance of Gland Pharma Ltd
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Gland Pharma Ltd has 8 directors - 4 independent and 1 executive. The board is chaired by Srinivas Sadu.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Srinivas Sadu | Executive Director · Chairperson | 2019-04-25 | 1 |
| UDO JAHANNES VETTER | Non-Executive - Independent Director | 2018-02-07 | 1 |
| Essaji Goolam Vahanvati | Non-Executive - Independent Director | 2020-09-30 | 2 |
| Satyanarayana Murthy Chavali | Non-Executive - Independent Director | 2018-11-20 | 2 |
| Naina Lal Kidwai | Non-Executive - Independent Director | 2021-05-17 | 3 |
| Jia Ai Zhang | Non-Executive - Non Independent Director | 2021-05-17 | 1 |
| Wenjie Zhang | Non-Executive - Non Independent Director | 2024-08-30 | 1 |
| Wei Huang | Non-Executive - Non Independent Director | 2024-11-04 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER |
| Nomination and remuneration committee | Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER, Wei Huang |
| Stakeholders Relationship Committee | Satyanarayana Murthy Chavali (Chairperson), Srinivas Sadu, Wenjie Zhang |
| Risk Management Committee | Naina Lal Kidwai (Chairperson), Srinivas Sadu, Jia Ai Zhang, Ravi Shekar Mitra |
| Corporate Social Responsibility Committee | Srinivas Sadu (Chairperson), Essaji Goolam Vahanvati, Jia Ai Zhang |
| ESOP Compensation Committee | Satyanarayana Murthy Chavali (Chairperson), Essaji Goolam Vahanvati, UDO JAHANNES VETTER |
Charges & Borrowings of Gland Pharma Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Sep 2012 | Icici Bank Limited | ₹100 Cr | Satisfied |
| 30 Jun 2012 | Syndicate Bank | ₹100 Cr | Satisfied |
| 06 Sep 2005 | The Bank of Nova Scotia | ₹140 Cr | Satisfied |
| 13 Dec 2004 | Syndicate Bank | ₹7.5 Cr | Satisfied |
| 09 Sep 2004 | Export Import Bank of India | ₹10 Cr | Satisfied |
Total charge records: 11 View all charges
Employees and EPFO Compliance at Gland Pharma Ltd
View historical data on people associated with Gland Pharma Ltd, including employment history and EPFO contributions.
Employee Count & EPFO Data of Gland Pharma Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Gland Pharma Ltd
GSTIN & GST Filing Data of Gland Pharma Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Gland Pharma Ltd
Credit Ratings, Legal Cases & Regulatory Alerts of Gland Pharma Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Gland Pharma Ltd
MSME Payment Delays by Gland Pharma Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Gland Pharma Ltd
Subsidiaries & Group Companies of Gland Pharma Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Gland Pharma Ltd with ownership details.
MCA Filings & Documents of Gland Pharma Ltd
MCA Filings & Documents of Gland Pharma Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Gland Pharma Ltd
Recent News on Gland Pharma Ltd
Frequently Asked Questions about Gland Pharma Ltd
Gland Pharma Ltd is an active public limited company in the healthcare sector based in Medchal Malkajgiri District Hyderabad, Telangana, India. It was incorporated on 20 March 1978 (48+ years old) and is registered under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND. The company has 4,769 employees.
Gland Pharma Ltd reported revenue of ₹5,830.11 Cr for FY 2025 (up 0.00% YoY).
The current directors of Gland Pharma Ltd are:
- Essaji Goolam Vahanvati
- Udo Jahannes Vetter
- Jia Ai Zhang
- Srinivas Sadu
- Naina Lal Kidwai
- Sampath Kumar Pallerlamudi
- Ravi Shekhar Mitra
- Shyamakant Binda Giri
- Satyanarayana Murthy Chavali
- Wenjie Zhang
- Wei Huang
- Shyamakant Binda Giri
The primary industry of Gland Pharma Ltd is healthcare. The company specifically operates in medical and laboratory equipment. The company is currently active in this sector.
Yes. Gland Pharma Ltd is listed on both BSE (code: 543245) and NSE (symbol: GLAND).
Gland Pharma Ltd can be reached at the registered office: Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, AmmaM, Medchal Malkajgiri District Hyderabad, Telangana, India – 500043, or through the website glandpharma.com.